- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hepatocellular carcinoma (HCC)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1724KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 687KB)
Atezolizumab + bevacizumab – July 2020
Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL, Solution concentrate for I.V. infusion 840 mg in 14 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin®
Last updated
5 March 2021
